Companies in the News

- May 23, 2018
Indigo Named #18 On 2018 CNBC Disruptor 50 List, Which Spotlights Companies That Are Changing Their
Indigo is recognized alongside most ambitious and innovative companies representing breakthrough ideas from all over the world Boston, Massachusetts, May 22, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has been named to the sixth annual CNBC Disruptor 50 List, a ranked list of the most ambitious and innovative companies representing breakthrough ideas from all over the world. Indigo’s #18 ranking caps a remarka
- May 9, 2018
Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Pro
-- Strategic focus on unleashing therapeutic potential of specific orphan GPCRs, including novel family of Mas-Related G-Protein Receptors (Mrgprs) -- Opportunity to pursue novel therapeutics for a broad range of indications; initial focus on neuro-immuno-inflammatory and autoreactive diseases -- Series A investors include The Column Group, 5AM Ventures and Osage University Partners -- Co-founders bring deep expertise in GPCR scientific research and drug development, and prov
- May 3, 2018
Unity Biotech IPO Raises $85M to Test Drugs for Diseases of Aging
Xconomy San Francisco — Unity Biotechnology has yet to show that its drugs can treat diseases of aging in humans, but it now has $85 million to start those tests. The Brisbane, CA, drug developer priced its initial public offering late Wednesday by selling 5 million shares at $17 apiece, the midpoint of the $16 to $18 range it had previously set. Shares are expected to begin trading Thursday on the Nasdaq exchange under the stock symbol “UBX.” Unity aims to treat diseases of